We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Checkpoint Protein Expression in Tumor Microenvironment Defines Prognosis of Hodgkin Lymphoma Patients

By LabMedica International staff writers
Posted on 04 Jan 2022
Print article
Image: Bone marrow aspirate from a patient with classical Hodgkin Lymphoma with large multinucleated Reed-Sternberg cells. “Hodgkin cells” are mononuclear while “Reed-Sternberg” cells are multinucleate forms (Photo courtesy of Nidia P. Zapata, MD and Espinoza-Zamora Ramiro)
Image: Bone marrow aspirate from a patient with classical Hodgkin Lymphoma with large multinucleated Reed-Sternberg cells. “Hodgkin cells” are mononuclear while “Reed-Sternberg” cells are multinucleate forms (Photo courtesy of Nidia P. Zapata, MD and Espinoza-Zamora Ramiro)
In Hodgkin lymphoma, B-lymphocytes start to multiply in an abnormal way and begin to collect in certain parts of the lymphatic system, such as the lymph nodes (glands). The affected lymphocytes lose their infection-fighting properties, making one more vulnerable to infection.

In classical Hodgkin lymphoma (cHL), sparse malignant Hodgkin Reed-Sternberg (HRS) cells are embedded into extensive tumor microenvironment (TME) consisting mostly of benign immune cells, such as T and B lymphocytes, macrophages, eosinophils, plasma cells, and mast cells.

Clinical Scientists at the Helsinki University Hospital (Helsinki, Finland) and their colleagues studied clinical data and formalin-fixed paraffin-embedded (FFPE) diagnostic tumor tissue samples from patients with primary cHL diagnosed between years 1993- 2012 and treated or followed. The patients were divided into two cohorts: the first cohort, “gene expression cohort”, consisted of 88 patients, and the second cohort, “immunohistochemistry (IHC) cohort”, of 131 patients.

The scientists used the NanoString nCounter digital gene expression profiling with 770-gene PanCancer Immune Profiling Panel (XT-CSO-HIP1-12, NanoString Technologies, Seattle, WA, USA) for gene expression profiling. To assess the proportions of the distinct immune cells in the TME, they applied CIBERSORT (Stanford University, Stanford, CA, USA) for the gene expression cohort, and multiplex immunohistochemistry to characterize the immunoprofile of cHL TME, and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and non-inflamed TME. Several macrophage-related genes were upregulated in samples with the non-T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages.

The investigators reported that a cluster with high proportions of checkpoint protein (PD-1, PD-L1, IDO-1, LAG-3, and TIM-3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs. 96%), and remained as an independent prognostic factor for OS in multivariable analysis (HR 4.34). cHLs with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples and in an expansion cohort of 84 cHL relapse samples.

The authors concluded that their findings provide novel, more accurate information on the composition of different immune cells, checkpoint molecules, and their relationship in the heterogeneous cHL TME. Furthermore, the data recognize the prognostic impact of T cell and Tumor-Associated Macrophage (TAM) mediated checkpoint molecules on the survival of cHL patients. The study was published on December 23 2021 in the journal Blood Advances.

Related Links:
Helsinki University Hospital
NanoString Technologies
CIBERSORT


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.